Skip to main content
SpringerLink
Log in

The RapidMist™ System for Buccal Delivery of Insulin

  • Chapter
  • First Online:
Mucosal Delivery of Biopharmaceuticals

  • 2300 Accesses

Abstract

Multiple insulin injections are often required in patients with diabetes mellitus in order to achieve optimal glycemic control. This may reduce patient compliance and increase the risk of long-term microvascular complications in patients. To improve patient compliance, research efforts are focused towards development of needle-free method for insulin delivery. Though a number of different delivery systems and routes have been evaluated for insulin delivery, oral insulin spray formulation offers a number of advantages over others. Oral-lyn™, an oral insulin spray formulation, has been developed by Generex Biotechnology. This delivery system is convenient for patients and can be self-administered using RapidMist™ technology. Insulin is sprayed via the RapidMist™ device into the mouth via an aerosolized spray. Tasteless mist of recombinant human insulin is thus administered to the buccal mucosa. Human studies revealed that absorption of insulin from the formulation is in direct proportion to the amount administered. Insulin delivered via RapidMist™ technology shows a faster onset of action and a shorter duration of action when compared to regular insulin given subcutaneously. Also discussed in this chapter is the safety profile, mechanism of action, and findings of various studies performed on RapidMist™ system.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.

    Article  PubMed  Google Scholar 

  2. Varshosaz J. Insulin delivery system for controlling diabetes. Recent Pat Endocr Metab Immune Drug Discov. 2007;1(1):25–40.

    Article  CAS  Google Scholar 

  3. Kumria R, Goomber G. Emerging trends in insulin delivery: buccal route. J Diabetol. 2011;2(1):1–9.

    Article  Google Scholar 

  4. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124(1 Pt 2):136–45.

    Article  CAS  PubMed  Google Scholar 

  5. Bernstein G. Delivery of insulin to the buccal mucosa utilizing the RapidMist system. Expert Opin Drug Deliv. 2008;5(9):1047–55.

    Article  CAS  PubMed  Google Scholar 

  6. Lee VH. Enzymatic barriers to peptide and protein absorption. Crit Rev Ther Drug Carrier Syst. 1988;5(2):69–97.

    CAS  PubMed  Google Scholar 

  7. Heinemann L, Jacques Y. Oral insulin and buccal insulin: a critical reappraisal. J Diabetes Sci Technol. 2009;3(3):568–84.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Chidambaram N, Srivatsava AK. Buccal drug delivery systems. Drug Dev Ind Pharm. 1995;21(9):1009–36.

    Article  CAS  Google Scholar 

  9. al-Waili NS. Sublingual human insulin for hyperglycaemia in type I diabetes. J Pak Med Assoc. 1999;49(7):167–9.

    CAS  PubMed  Google Scholar 

  10. Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri P. Factors and strategies for improving buccal absorption of peptides. Eur J Pharm Biopharm. 2001;51(2):93–109.

    Article  CAS  PubMed  Google Scholar 

  11. Rossi S, Sandri G, Caramella CM. Buccal drug delivery: A challenge already won? Drug Discov Today Technol. 2005;2(1):59–65.

    Article  CAS  Google Scholar 

  12. Oh CK, Ritschel WA. Biopharmaceutic aspects of buccal absorption of insulin. Methods Find Exp Clin Pharmacol. 1990;12(3):205–12.

    CAS  PubMed  Google Scholar 

  13. Oh CK, Ritschel WA. Absorption characteristics of insulin through the buccal mucosa. Methods Find Exp Clin Pharmacol. 1990;12(4):275–9.

    CAS  PubMed  Google Scholar 

  14. Generex Biotechnology Corp. Data on File, 2008.

    Google Scholar 

  15. Modi P, Mihic M, Lewin A. The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist System. Diabetes Metab Res Rev. 2002;18(Suppl 1):S38–42.

    Google Scholar 

  16. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977–86.

    Article  Google Scholar 

  17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53.

    Article  Google Scholar 

  18. International Diabetes Federation Guideline Development Committee. Guideline for Management of Postmeal Glucose. Brussels: International Diabetes Federation; 2007.

    Google Scholar 

  19. Berger M, Cuppers HJ, Hegner H, Jorgens V, Berchtold P. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care. 1982;5(2):77–91.

    Article  CAS  PubMed  Google Scholar 

  20. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care. 1984;7(2):188–99.

    Article  PubMed  Google Scholar 

  21. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev. 1999;35(2–3):235–47.

    Article  CAS  PubMed  Google Scholar 

  22. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care. 1981;4(3):366–76.

    Article  CAS  PubMed  Google Scholar 

  23. Almér LO, Wollmer P, Jonson B, Troedsson Almér A. Insulin inhalation with absorption enhancer at meal-times results in almost normal postprandial insulin profiles. Clin Physiol Funct Imaging. 2002;22(3):218–21.

    Article  PubMed  Google Scholar 

  24. Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Clin Ther. 2004;26(12):2084–91.

    Article  CAS  PubMed  Google Scholar 

  25. Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I. Dose-response relationship of oral insulin spray in healthy subjects. Diabetes Care. 2005;28(6):1353–7.

    Article  CAS  PubMed  Google Scholar 

  26. Pozzilli P, Manfrini S, Costanza F, Coppolino G, Cavallo MG, Fioriti E, Modi P. Biokinetics of buccal spray insulin in patients with type 1 diabetes. Metabolism. 2005;54(7):930–4.

    Article  CAS  PubMed  Google Scholar 

  27. Guevara-Aguirre J, Guevara-Aguirre M, Saavedra J, Bernstein G, Rosenbloom AL. Comparison of oral insulin spray and subcutaneous regular insulin at mealtime in type 1 diabetes. Diabetes Technol Ther. 2007;9(4):372–6.

    Article  CAS  PubMed  Google Scholar 

  28. Guevara-Aguirre J, Guevara-Aguirre M, Saavedra J, Bernstein G. 6-month safety and efficacy of lunch-time oral insulin in juvenile type-1 DM subjects receiving basal glargine insulin and pre-breakfast and pre-dinner S.C. regular insulin (abstract), Endocrine Society 89th Annual Meeting, 2007.

    Google Scholar 

  29. Guevara-Aguirre J, Guevara-Aguirre M, Saavedra J. A comparison of metabolic control of preprandial S.C. regular insulin versus prandial split doses of an oral insulin (Generex Oral-lyn) in well controlled type 1 diabetes mellitus subjects maintained on twice daily NPH insulin (abstract), Endocrine Society 89th Annual Meeting, 2007.

    Google Scholar 

  30. Cernea S, Kidron M, Wohlgelernter J, Raz I. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. Clin Ther. 2005;27(10):1562–70.

    Article  CAS  PubMed  Google Scholar 

  31. Guevara-Aguirre J, Guevara M, Saavedra J, Mihic M, Modi P. Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents. Diabetes Technol Ther. 2004;6(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  32. Guevara-Aguirre J, Guevara M, Saavedra J, Mihic M, Modi P. Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study. Diabetes Metab Res Rev. 2004;20(6):472–8.

    Article  CAS  PubMed  Google Scholar 

  33. Palermo A, Napoli N, Manfrini S, Lauria A, Strollo R, Pozzilli P. Buccal spray insulin in subjects with impaired glucose tolerance: the prevoral study. Diabetes Obes Metab. 2011;13(1):42–6.

    Article  CAS  PubMed  Google Scholar 

  34. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002;4(5):673–82.

    Article  PubMed  Google Scholar 

  35. Generex Biotechnology Corp. Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin, ClinicalTrials.gov Identifier: NCT00668850, 2008.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mehr Chand Polytechnic College, Jalandhar, Panjab, India

    Meena Bansal & Sanjay Bansal

  2. Swift School of Pharmacy, Village Ghaggar Sarai, Rajpura, Panjab, India

    Rachna Kumria

Authors
  1. Meena Bansal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sanjay Bansal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rachna Kumria
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rachna Kumria .

Editor information

Editors and Affiliations

  1. IINFACTS - Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Instituto Superior de Ciências da Saúde-Norte, CESPU, Gandra, Portugal

    José das Neves

  2. NEWTherapies Group, INEB – Instituto de Engenharia Biomédica, Porto, Portugal

    Bruno Sarmento

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bansal, M., Bansal, S., Kumria, R. (2014). The RapidMist™ System for Buccal Delivery of Insulin. In: das Neves, J., Sarmento, B. (eds) Mucosal Delivery of Biopharmaceuticals. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-9524-6_19

Download citation

Publish with us

Policies and ethics

Search

Navigation